Nivolumab is a type of cancer treatment drug called immunotherapy. It's a treatment for a number of different types of cancer. It's also known as Opdivo. Depending on your cancer type you might have nivolumab on its own or in combination with other anti cancer drugs.

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult ...

When used together, nivolumab and ipilimumab can treat advanced melanoma more effectively than each drug on its own. This combination of two immunotherapy drugs can shrink tumors and help patients live longer.

The active substance in Opdivo, nivolumab, is a monoclonal antibody, a type of protein that has been designed to attach to a receptor called PD-1 found on cells of the immune system called T cells.

Nivolumab is produced from manufacturing-scale cell culture using a Chinese hamster ovary (CHO) cell line that was transfected with an expression vector containing coding sequences for the heavy and light chains of the nivolumab IgG.

Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.

Under the agreement between the companies in 2005, Medarex held an exclusive right of nivolumab in North America, and Ono retained the right in all other countries except North America. Bristol-Myers Squibb acquired Medarex in 2009, for $2.4B, largely on the strength of its checkpoint inhibitor program.

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

OPDIVO is an immunotherapy treatment that helps your immune system launch a response that fights cancer. OPDIVO (pronounced op-DEE-voh) is given as an infusion with chemotherapy every three weeks for nine weeks before surgery.

Non-specific immunotherapy uses cytokines, growth factors and other substances to give the immune system a boost to fight cancer. Cytokines are chemicals in the body that trigger the immune system to fight disease or germs that get into the body. But cytokines can also be made in the lab and used to treat cancer.

Manufactured By: Bristol Myers Squibb India Pvt. Ltd.

T cells are immune cells that fight infection. In T-cell therapy, the doctor removes T cells from the blood. Then, a laboratory adds specific proteins called receptors to the cells. The receptor allows those T cells to recognize cancer cells.

Researchers at Peter Mac have identified a new type of immunotherapy in solid tumours that tricks cancer cells into alerting our own immune system to destroy them. The research, published in Cancer Discovery in collaboration with Storm Therapeutics, uses a world-first drug that targets mRNA.

Naked monoclonal antibodies are the most common type used in cancer treatment. They're called naked because they're unattached to anything. These antibodies boost your immune system's response against the cancer, or block antigens that help the cancer grow and spread.

OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

OPDIVO is an immunotherapy treatment that works with the T cells of your immune system. healthcare team when discussing treatment decisions. Watch this video to see how OPDIVO can work with your immune system to help fight cancer.